BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. (Q51369014)
Jump to navigation
Jump to search
scientific article published on 19 October 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. |
scientific article published on 19 October 2016 |
Statements
1 reference
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. (English)
1 reference
Stephanie M McGregor
1 reference
James McElherne
1 reference
Agata Minor
1 reference
Jennifer Keller-Ramey
1 reference
Ryan Dunning
1 reference
Aliya N Husain
1 reference
Wickii Vigneswaran
1 reference
Carrie Fitzpatrick
1 reference
Thomas Krausz
1 reference
19 October 2016
1 reference
1 reference
60
1 reference
86-94
1 reference
Identifiers
1 reference